The round was led by pi Ventures, with participation from Bluehill Capital, SOSV, and a global syndicate of investors. With this round, Helex has raised over $6 million in total funding to date.

Helex is a therapeutics company developing a new class of targeted medicines for genetic kidney diseases using its proprietary LNP drug delivery and AI-based drug design platforms. With a world-class team of scientists and drug developers, Helex operates from New York, USA, and ASPIRE BioNEST, Hyderabad, India, and is supported by Bayer Co.Lab Cambridge.